Dr. Bertrand Routy MD, PhD is a young clinician-scientist (FRQS J1) and assistant professor in the hemato-oncology department at the CHUM (University of Montreal) with clinical experience in lung cancer. Since 2018, he has directed the onco-microbiome laboratory at the CRCHUM and the thoracic oncology biobank. Dr. Routy was instrumental in discovering the key role of the microbiome in the effectiveness of cancer immunotherapy and the deleterious impact of antibiotics.
Dr. Routy focuses on the use of the microbiome as a novel biomarker for the efficacy of immunotherapy as well as on strategies to change the composition of the microbiome in oncology. He is now leading microbiome-centered clinical trials. His research has led to the publication of more than 70 articles in journals such as Science, Nature Medicine and Annals of Oncology with more than 8,364 citations and h-index of 27. His laboratory is funded by several provincial and national grants as well as the Canada Research Chair of immunotherapy. In 2021, Dr. Routy received the Best Young Investigator Award from the University of Montreal and the Gairdner Foundation Early Career Investigator Award.